Arvinas to Present at Upcoming Investor Conferences
Arvinas to Present at Upcoming Investor Conferences
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
康涅狄格州纽黑文，2024年5月2日（GLOBE NEWSWIRE）——开发一种基于靶向蛋白质降解的新药物的临床阶段生物技术公司Arvinas, Inc.（纳斯达克股票代码：ARVN）今天宣布，管理层将参加即将举行的两次投资者会议：
-
BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas.
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company's website.
- 美银证券2024年医疗保健会议将于太平洋时间5月14日星期二下午3点在拉斯维加斯举行。
- 首席医学官诺亚·伯科维茨医学博士、博士和首席商务官兰迪·蒂尔博士将参加炉边谈话。将提供该演示文稿的网络现场直播 这里 以及公司网站的 “活动和演示” 部分。
-
UBS Spring Biotech Conferences on Tuesday, May 21.
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in investor 1x1 meetings.
- 瑞银春季生物技术会议将于5月21日星期二举行。
- 首席医学官诺亚·伯科维茨医学博士、博士和首席商务官兰迪·蒂尔博士将参加投资者1x1会议。
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and "undruggable" targets, the company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-102 for the treatment of patients with neurodegenerative disorders. For more information, visit www.arvinas.com.
关于阿维纳斯
Arvinas是一家处于临床阶段的生物技术公司，致力于通过发现、开发和商业化降解致病蛋白的疗法，改善患有使人衰弱和危及生命的疾病的患者的生活。Arvinas 使用其专有的 PROTAC Discovery Engine 平台用于设计针对嵌合体或 PROTAC 的蛋白水解 靶向蛋白质降解剂，旨在利用人体自身的天然蛋白质处置系统，有选择地高效地降解和去除致病蛋白。除了针对经过验证和 “不可药用” 的靶标的强大临床前PROTAC蛋白降解剂产品线外，该公司还有四个临床阶段研究项目：用于治疗局部晚期或转移性ER+/HER2-乳腺癌患者的vepdegestrant（ARV-471）；用于治疗转移性去势抵抗性前列腺癌男性的 ARV-766 和巴德加鲁胺；以及用于治疗转移性去势抗性前列腺癌的 ARV-102 神经退行性疾病患者。欲了解更多信息，请访问 www.arvinas.com。
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
联系人
投资者：
杰夫·博伊尔
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kathleen Murphy
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com
媒体：
凯瑟琳·墨菲
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com